Reply to letters on review ‘Evolving treatment strategies for myeloma’

por Morgan, G J, Davies, F E
Publicado 2005

Evolving treatment strategies for myeloma

por Morgan, G J, Davies, F E
Publicado 2005

Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical applica...

por Aronson, L I, Davenport, E L, Mirabella, F, Morgan, G J, Davies, F E
Publicado 2013

Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease bur...

por Giles, S.L., deSouza, N.M., Collins, D.J., Morgan, V.A., West, S., Davies, F.E., Morgan, G.J., Messiou, C.
Publicado 2015

Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?

por Pawlyn, C, Fowkes, L, Otero, S, Jones, J R, Boyd, K D, Davies, F E, Morgan, G J, Collins, D J, Sharma, B, Riddell, A, Kaiser, M F, Messiou, C
Publicado 2016

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients

por Walker, B A, Wardell, C P, Brioli, A, Boyle, E, Kaiser, M F, Begum, D B, Dahir, N B, Johnson, D C, Ross, F M, Davies, F E, Morgan, G J
Publicado 2014

P925: IMPACT OF PRIOR TREATMENT EXPOSURE ON THE EFFECTIVENESS OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED IN ROUTINE CLINICAL PR...

por Lee, H. C., Ramasamy, K., Macro, M., Davies, F. E., Abonour, R., van Rhee, F., Hungria, V. T., Puig, N., Ren, K., Silar, J., Enwemadu, V., Cherepanov, D., Stull, D. M., Leleu, X.
Publicado 2022

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

por Dimopoulos, M A, Leleu, X, Palumbo, A, Moreau, P, Delforge, M, Cavo, M, Ludwig, H, Morgan, G J, Davies, F E, Sonneveld, P, Schey, S A, Zweegman, S, Hansson, M, Weisel, K, Mateos, M V, Facon, T, Miguel, J F S
Publicado 2014

Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs

por Jones, J. R., Barber, A., Le Bihan, Y-V, Weinhold, N., Ashby, C., Walker, B. A., Wardell, C. P., Wang, H., Kaiser, M. F., Jackson, G. H., Davies, F. E., Chopra, R., Morgan, G. J., Pawlyn, C.
Publicado 2021

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

por Pawlyn, C, Bright, M D, Buros, A F, Stein, C K, Walters, Z, Aronson, L I, Mirabella, F, Jones, J R, Kaiser, M F, Walker, B A, Jackson, G H, Clarke, P A, Bergsagel, P L, Workman, P, Chesi, M, Morgan, G J, Davies, F E
Publicado 2017

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

por Rasche, L., Chavan, S. S., Stephens, O. W., Patel, P. H., Tytarenko, R., Ashby, C., Bauer, M., Stein, C., Deshpande, S., Wardell, C., Buzder, T., Molnar, G., Zangari, M., van Rhee, F., Thanendrarajan, S., Schinke, C., Epstein, J., Davies, F. E., Walker, B. A., Meissner, T., Barlogie, B., Morgan, G. J., Weinhold, N.
Publicado 2017

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma

por Rasche, L, Alapat, D, Kumar, M, Gershner, G, McDonald, J, Wardell, C.P, Samant, R, Van Hemert, R, Epstein, J, Williams, A.F, Thanendrarajan, S, Schinke, C, Bauer, M, Ashby, C, Tytarenko, R.G, van Rhee, F, Walker, B.A, Zangari, M, Barlogie, B, Davies, F.E, Morgan, G.J, Weinhold, N
Publicado 2018

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial

por Jones, J R, Cairns, D A, Gregory, W M, Collett, C, Pawlyn, C, Sigsworth, R, Striha, A, Henderson, R, Kaiser, M F, Jenner, M, Cook, G, Russell, N H, Williams, C, Pratt, G, Kishore, B, Lindsay, J, Drayson, M T, Davies, F E, Boyd, K D, Owen, R G, Jackson, G H, Morgan, G J
Publicado 2016

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker

por Chavan, S S, He, J, Tytarenko, R, Deshpande, S, Patel, P, Bailey, M, Stein, C K, Stephens, O, Weinhold, N, Petty, N, Steward, D, Rasche, L, Bauer, M, Ashby, C, Peterson, E, Ali, S, Ross, J, Miller, V A, Stephens, P, Thanendrarajan, S, Schinke, C, Zangari, M, van Rhee, F, Barlogie, B, Mughal, T I, Davies, F E, Morgan, G J, Walker, B A
Publicado 2017

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients

por Shah, V, Sherborne, A L, Walker, B A, Johnson, D C, Boyle, E M, Ellis, S, Begum, D B, Proszek, P Z, Jones, J R, Pawlyn, C, Savola, S, Jenner, M W, Drayson, M T, Owen, R G, Houlston, R S, Cairns, D A, Gregory, W M, Cook, G, Davies, F E, Jackson, G H, Morgan, G J, Kaiser, M F
Publicado 2018

Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach

por Went, M, Sud, A, Law, P J, Johnson, D C, Weinhold, N, Försti, A, van Duin, M, Mitchell, J S, Chen, B, Kuiper, R, Stephens, O W, Bertsch, U, Campo, C, Einsele, H, Gregory, W M, Henrion, M, Hillengass, J, Hoffmann, P, Jackson, G H, Lenive, O, Nickel, J, Nöthen, M M, da Silva Filho, M I, Thomsen, H, Walker, B A, Broyl, A, Davies, F E, Langer, C, Hansson, M, Kaiser, M, Sonneveld, P, Goldschmidt, H, Hemminki, K, Nilsson, B, Morgan, G J, Houlston, R S
Publicado 2017